Skip to main content
. 2016 Feb 22;7(3):165–177. doi: 10.1007/s12672-016-0256-3

Table 5.

Summary of a number of large studies that reported associations between TERT promoter mutations and clinicopathological features of FTC or ATC

FTC ATC
Muzza et al. 2015 [30] Melo M et al. 2014 [36] Wang N et al. 2014 [34] Liu T et al. 2014 [37] Shi X et al. 2015 [28]
Mutant (8) Wild (50) P value Mutant (12) Wild (58) P value Mutant (9) Wild (42) P value Mutant (8) Wild (28) P value Mutant (18) Wild (28) P value
Age 66 (48–81) 56 (18–85) 0.04 63.8 ± 11.0 49.3 ± 16.3 0.004 66 ± 16 54 ± 19 0.052 69 (31–83) 54 (17–77) 0.05 68.7 ± 12.5 60.4 ± 11.2 0.023
Size 5.4 4.09 0.1 4.4 ± 2.5 4.4 ± 2.6 0.96 5.0 (3.5–6.7) 6.0 (3.5–7.5) 0.46
ETE 5/8 (62.5 %) 24/50 (48 %) 0.7 3/8 (37.5 %) 5/41 (12.2 %) 0.08 18/18 (100 %) 22/24 (91.6 %) 0.49
Vascular invasion 8/10 (80 %) 31/43 (72.1 %) 0.61
LNM 7/8 (87.5 %) 46/50 (92 %) 0.7 3/12 (25 %) 5/35 (14.3 %) 0.39 11/17 (64.7 %) 13/21 (61.9 %) 0.86
Distant mets 5/5 (100 %) 3/26 (11.5 %) 0.001 15/18 (83.3 %) 8/26 (30.8 %) 0.001
TNM III and IV 6/8 (75 %) 23/50 (46 %) 0.02 5/6 (83.3 %) 8/23 (34.8 %) 0.007
Recurrence 5/8 (62.5 %) 11/50 (22 %) 0.03
Death 2/12 (16.7 %) 0/58 (0) <0.001

ETE extrathyroidal extension/invasion, LNM lymph node metastases, Mets metastases, TNM tumor node metastasis staging system